Method for treatment of diseases

Abstract

The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a danazol compound to the animal.

1 - 35 . (canceled) 
     
     
         36 . A pharmaceutical dosage form, comprising a danazol compound in an amount of about 5 mg to about 45 mg. 
     
     
         37 . The pharmaceutical dosage form of  claim 36 , wherein the danazol compound is danazol. 
     
     
         38 . The pharmaceutical dosage form of  claim 36 , wherein the dosage form is a solid dosage form. 
     
     
         39 . The pharmaceutical dosage form of  claim 36 , wherein the dosage form is a liquid dosage form. 
     
     
         40 . The pharmaceutical dosage form of  claim 36 , further comprising a pharmaceutically-acceptable carrier. 
     
     
         41 . A pharmaceutical composition, comprising a danazol compound in a concentration of 0.0001 μM to 5 μM, wherein the composition is formulated to be administered topically to the eye. 
     
     
         42 . The pharmaceutical composition of  claim 41 , wherein the concentration of the danazol compound is 0.1 μM to 1.0 μM. 
     
     
         43 . The pharmaceutical composition of  claim 41 , wherein the concentration of the danazol compound is 0.1 μM to 0.5 μM. 
     
     
         44 . The pharmaceutical composition of  claim 41 , wherein the concentration of the danazol compound is about 0.1 μM. 
     
     
         45 . The pharmaceutical composition of  claim 41 , wherein the dosage form is selected from the group consisting of solutions, suspensions, dispersions, drops, gels, hydrogels and ointments. 
     
     
         46 . The pharmaceutical composition of  claim 41 , further comprising an absorption or permeation enhancer. 
     
     
         47 . The pharmaceutical composition of  claim 41 , further comprising a thickening agent or viscosity enhancer to increasing the residence time of the danazol compound in the eye. 
     
     
         48 . The pharmaceutical composition of  claim 41 , wherein the danazol compound is danazol. 
     
     
         49 . The pharmaceutical composition of  claim 41 , further comprising a pharmaceutically-acceptable carrier.